This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chow, K C Articles by Ross, W E Search for Related Content PubMed PubMed Citation Articles by Chow, K C Articles by Ross, W E

Topoisomerase-specific drug sensitivity in relation to cell cycle progression.

Department of Pharmacology, University of Florida, College of Medicine, Gainesville 32610.

ABSTRACT

The nuclear enzyme DNA topoisomerase II catalyzes the breakage and resealing of duplex DNA and plays an important role in several genetic processes. It also mediates the DNA cleavage activity and cytotoxicity of clinically important anticancer agents such as etoposide. We have examined the activity of topoisomerase II during the first cell cycle of quiescent BALB/c 3T3 cells following serum stimulation. Etoposide-mediated DNA break frequency in vivo was used as a parameter of topoisomerase II activity, and enzyme content was assayed by immunoblotting. Density-arrested A31 cells exhibited a much lower sensitivity to the effects of etoposide than did actively proliferating cells. Upon serum stimulation of the quiescent cells, however, there was a marked increase in drug sensitivity which began during S phase and reached its peak just before mitosis. Maximal drug sensitivity during this period was 2.5 times greater than that of log-phase cells. This increase in drug sensitivity was associated with an increase in intracellular topoisomerase II content as determined by immunoblotting. The induction of topoisomerase II-mediated drug sensitivity was aborted within 1 h of exposure of cells to the protein synthesis inhibitor cycloheximide, but the DNA synthesis inhibitor aphidicolin had no effect. In contrast to the sensitivity of cells to drug-induced DNA cleavage, maximal cytotoxicity occurred during S phase. A 3-h exposure to cycloheximide before etoposide treatment resulted in nearly complete loss of cytotoxicity. Our findings indicate that topoisomerase II activity fluctuates with cell cycle progression, with peak activity occurring during the G2 phase. This increase in topoisomerase II is protein synthesis dependent and may reflect a high rate of enzyme turnover. The dissociation between maximal drug-induced DNA cleavage and cytotoxicity indicates that the topoisomerase-mediated DNA breaks may be necessary but are not sufficient for cytotoxicity and that the other factors which are particularly expressed during S phase may be important as well.

This article has been cited by other articles:

• Patre, M., Tabbert, A., Hermann, D., Walczak, H., Rackwitz, H.-R., Cordes, V. C., Ferrando-May, E. (2006). Caspases Target Only Two Architectural Components within the Core Structure of the Nuclear Pore Complex. J. Biol. Chem. 281: 1296-1304 [Abstract] [Full Text]  
• Reis, C., Giocanti, N., Hennequin, C., Megnin-Chanet, F., Fernet, M., Filomenko, R., Bettaieb, A., Solary, E., Favaudon, V. (2005). A role for PKC{zeta} in potentiation of the topoisomerase II activity and etoposide cytotoxicity by wortmannin. Molecular Cancer Therapeutics 4: 1457-1464 [Abstract] [Full Text]  
• Kurz, E. U., Wilson, S. E., Leader, K. B., Sampey, B. P., Allan, W. P., Yalowich, J. C., Kroll, D. J. (2001). The Histone Deacetylase Inhibitor Sodium Butyrate Induces DNA Topoisomerase II{alpha} Expression and Confers Hypersensitivity to Etoposide in Human Leukemic Cell Lines. Molecular Cancer Therapeutics 1: 121-131 [Abstract] [Full Text]  
• Peng, Y.-C., Kuo, F., Breiding, D. E., Wang, Y.-F., Mansur, C. P., Androphy, E. J. (2001). AMF1 (GPS2) Modulates p53 Transactivation. Mol. Cell. Biol. 21: 5913-5924 [Abstract] [Full Text]  
• Hsu, N.-Y., Ho, H.-C., Chow, K.-C., Lin, T.-Y., Shih, C.-S., Wang, L.-S., Tsai, C.-M. (2001). Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker of Non-Small Cell Lung Cancer. Cancer Res. 61: 2727-2731 [Abstract] [Full Text]  
• Ongkeko, W, Ferguson, D., Harris, A., Norbury, C (1995). Inactivation of Cdc2 increases the level of apoptosis induced by DNA damage. J. Cell Sci. 108: 2897-2904 [Abstract]